E-drug: NEW: Therapeutics Letter 34 now on the web
-------------------------------------------------------------------------
I would like to bring to your attention the March / April 2000 issue (#34)
of the Therapeutics Letter on New Drugs (orlistat, raloxifene,
spironolactone) that was just made available a few minutes ago on the
Therapeutics Initiative web-site at http://www.ti.ubc.ca/pages/letter34.htm
I invite you to drop by and have a look at this Letter. Please feel free to
forward this message to any of your friends or colleagues that might be
interested in this topic.
We would appreciate receiving your comments on this Therapeutics Letter and
its possible implications in clinical practice.
Regards,
Ciprian D Jauca
Program Coordinator
Therapeutics Initiative - Evidence Based Drug Therapy
University of British Columbia
2176 Health Sciences Mall
Vancouver, BC V6T 1Z3
Canada
E-mail: jauca@ti.ubc.ca
Phone: +1 (604) 822-0700
GSM Mobile Phone: +1 (604) 722-2075
Fax: +1 (604) 822-0701
Web: http://www.ti.ubc.ca
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.